AbbVie Inc. (abbv)
ABBV Valuation
| P/E (trailing) | 75.09 |
| P/E (forward) | 16.30 |
| EV/EBITDA | 17.32 |
| Price/Sales | 7.28 |
| Price/Book | -78.92 |
| Market cap | $468.43B |
Start Free — open ABBV in Vest Terminal
Access live data, filings, ownership, and analysis for AbbVie Inc..
AbbVie Inc. FAQ
What does AbbVie Inc. (ABBV) do?
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruv…
What is ABBV's P/E ratio?
AbbVie Inc. has a trailing P/E of 75.09× based on publicly available market data.
Does ABBV pay a dividend?
Indicated dividend yield: 2.6%. Confirm ex-dates and payout history in Vest Terminal.
What sector is ABBV in?
AbbVie Inc. is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is ABBV's market capitalization?
Approximate market cap: $468.43B.
What are the main risks for ABBV?
Key risks include elevated valuation, among factors on this page.
What are the strengths of ABBV?
Potential positives include revenue growth of 10.2% year-over-year, earnings growth of 2.9% year-over-year.
Where can I get analyst estimates for ABBV?
Public analyst price targets and consensus for AbbVie Inc. are on the free /stocks/abbv/estimates page. Deeper estimate history and models are available in Vest Terminal.